Brian Rosenberger Zynerba Pharmaceuticals, Inc. (ZYNE) insider trading activity

Brian Rosenberger is VP, Commercial & Business Dev. of Zynerba Pharmaceuticals, Inc.. Currently has a direct ownership of 0 shares of ZYNE, which is worth approximately $0. The most recent transaction as insider was on Oct 10, 2023, when has been sold 369,559 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Brian Rosenberger Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 10 2023	SELL Disposition due to a tender of shares in a change of control transaction	-	369,559 Reduced 100.0%	0 Common Stock
Oct 10 2023	BUY Grant, award, or other acquisition	-	120,000 Added 28.57%	300,000 Common Stock
Sep 13 2023	SELL Open market or private sale	$8,526 $1.33 p/Share	6,411 Reduced 2.5%	249,559 Common Stock
Sep 12 2023	BUY Grant, award, or other acquisition	-	22,200 Added 7.98%	255,970 Common Stock
Feb 08 2023	SELL Payment of exercise price or tax liability	$3,087 $0.6 p/Share	5,145 Reduced 2.15%	233,770 Common Stock
Feb 07 2023	BUY Grant, award, or other acquisition	-	14,926 Added 5.88%	238,915 Common Stock
Feb 01 2023	SELL Payment of exercise price or tax liability	$2,885 $0.6 p/Share	4,809 Reduced 2.1%	223,989 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	13,950 Added 5.75%	228,798 Common Stock
Jan 24 2023	BUY Grant, award, or other acquisition	-	120,000 Added 35.84%	214,848 Common Stock
Jan 23 2023	SELL Open market or private sale	$7,597 $0.6 p/Share	12,663 Reduced 11.78%	94,848 Common Stock
Jul 19 2022	SELL Open market or private sale	$4,718 $1.1 p/Share	4,289 Reduced 3.84%	107,511 Common Stock
Jul 18 2022	BUY Grant, award, or other acquisition	-	14,800 Added 11.69%	111,800 Common Stock
Jan 26 2022	BUY Grant, award, or other acquisition	-	60,000 Added 38.22%	97,000 Common Stock
Jan 21 2021	BUY Grant, award, or other acquisition	-	37,000 Added 50.0%	37,000 Common Stock

Brian Rosenberger

VP, Commercial & Business Dev.

Devon, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZYNE shares.

Notify only if

Value

Insider Trading

Get notified when an Zynerba Pharmaceuticals, Inc. insider buys or sells ZYNE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Zynerba Pharmaceuticals, Inc.

Track Activities on ZYNE

Account